Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
6Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
CNS Pharmaceuticals, Inc. (CNSP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
25Total relationships
4Distinct source URLs
20High confidence
0.881Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
CNS Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CORTICE-BIOSCIENCES-INC
CORTICE-BIOSCIENCES-INC
92%
The Company entered into an Exclusive License Agreement with Cortice Biosciences, Inc. pursuant to which Cortice granted the Company an exclusive license to the intellectual property rights
ANIMAL-LIFE-SCIENCES-LLC
ANIMAL-LIFE-SCIENCES-LLC
90%
10.6 Sublicense Agreement between CNS Pharmaceuticals, Inc. and Animal Life Sciences, LLC. dated August 31, 2018
HOUSTON-PHARMACEUTICALS-INC
HOUSTON-PHARMACEUTICALS-INC
90%
10.1 Amended And Restated Patent License Agreement effective as of December 28, 2017 between CNS Pharmaceuticals, Inc. and Houston Pharmaceuticals, Inc.
REATA-PHARMACEUTICALS-INC
REATA-PHARMACEUTICALS-INC
90%
10.2 Collaboration and Asset Purchase Agreement between CNS Pharmaceuticals, Inc. and Reata Pharmaceuticals, Inc. dated November 21, 2017
WPD-PHARMACEUTICALS-INC
WPD-PHARMACEUTICALS-INC
90%
10.5 Sublicense Agreement between CNS Pharmaceuticals, Inc. and WPD Pharmaceuticals, Inc. dated August 30, 2018
Reciprocal relationship from BDRX graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from BDRX graph: , contraindications or other safety information, including boxed warnings; •…
CNS Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
A-G-P-ALLIANCE-GLOBAL-PARTNERS
A-G-P-ALLIANCE-GLOBAL-PARTNERS
90%
10.27 Placement Agency Agreement between CNS Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners
CORTICE-BIOSCIENCES-INC
CORTICE-BIOSCIENCES-INC
90%
10.25 Stock Purchase Agreement between CNS Pharmaceuticals, Inc. and Cortice Biosciences, Inc.
Reciprocal relationship from ATNM graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ATNM g…
& Oncology Neurological disorders represent a staggering public health crisis of global proportions. The World Health Organization (“WHO”) and the Global Burden of Disease study identify neurological…
Reciprocal relationship from BDRX graph: ther companies in the sustained release space include Medincell S.A., InnoCore Technologies BV, GP Pharm, S.A., Peptron, Inc., and Nanomi B.V. From a technolo…
Reciprocal relationship from ASTS graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ASTS graph: Reciprocal relationship from CNSP graph: Reciprocal relationship from ASTS g…
CNS Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
CNSP-DEBT-8753
Warrants outstanding: 0.001
90%
xbrl warrant detail from xbrl 2025-12-31.
CNSP-DEBT
Debt stack $449,874
90%
Market cache reports total debt of $449,874.
CNSP-DEBT-8754
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
CNS Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for CNS Pharmaceuticals, Inc..
CNS Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
CNSP-OWNER-UBS-GROUP-AG
UBS Group AG
95%
13F/ownership overlay lists UBS Group AG; shares held 729; ownership 0.09%; value $5,314; as of 2026-03-31.
CNSP-OWNER-IKARIAN-CAPITAL-LLC
Ikarian Capital, LLC
95%
13F/ownership overlay lists Ikarian Capital, LLC; shares held 45,830; ownership 5.65%; value $334,100; as of 2025-12-31.
CNSP-OWNER-BARRETT-COMPANY-INC
Barrett & Company, Inc.
95%
13F/ownership overlay lists Barrett & Company, Inc. ; shares held 8; value $58; as of 2026-03-31.
CNSP-OWNER-STONEPINE-CAPITAL-MANAGEMENT-LLC
Stonepine Capital Management, LLC
95%
13F/ownership overlay lists Stonepine Capital Management, LLC; shares held 48,827; ownership 6.02%; value $355,948; as of 2025-12-31.
CNSP-OWNER-SOUND-INCOME-STRATEGIES-LLC
Sound Income Strategies, LLC
95%
13F/ownership overlay lists Sound Income Strategies, LLC; shares held 16; value $116; as of 2026-03-31.
CNSP-OWNER-DRW-SECURITIES-LLC
DRW Securities, LLC
95%
13F/ownership overlay lists DRW Securities, LLC; shares held 15,429; ownership 1.90%; value $112,477; as of 2025-12-31.
CNSP-OWNER-BOOTHBAY-FUND-MANAGEMENT-LLC
Boothbay Fund Management, LLC
95%
13F/ownership overlay lists Boothbay Fund Management, LLC; shares held 13,524; ownership 1.67%; value $98,589; as of 2025-12-31.
CNSP-OWNER-DANSKE-BANK-A-S
Danske Bank A/s
95%
13F/ownership overlay lists Danske Bank A/s; shares held 1; value $7; as of 2025-12-31.
CNSP-OWNER-MAI-CAPITAL-MANAGEMENT
MAI Capital Management
95%
13F/ownership overlay lists MAI Capital Management; shares held 3; value $21; as of 2025-12-31.
CNSP-OWNER-BANK-OF-AMERICA-CORPORATION
Bank of America Corporation
95%
13F/ownership overlay lists Bank of America Corporation; shares held 4; value $29; as of 2025-12-31.
CNS Pharmaceuticals, Inc. Extended Supply Chain Network
